Ingevity Corporation (NGVT) Market Cap & Valuation Ratios
Ingevity Corporation (NGVT) has a market cap of $2.4B, a trailing P/E of 46.4 and a price-to-sales ratio of 2.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NGVTIngevity CorporationFollow NGVT — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- 46.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
specialty chemicals · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NGVT | 2.4 | 46.4 | 3.0 | 6.7 | 6.5% | -1% | 36% | 29% |
| CBT | 3.8 | 20.7 | 1.3 | 7.2 | 7.4% | -5% | 14% | 10% |
| AVNT | 3.8 | 22.2 | 1.6 | 10.3 | 5.1% | +2% | 9% | 6% |
| ASH | 3.3 | 69.5 | 2.3 | 13.0 | 7.5% | -1% | 7% | 3% |
| WDFC | 2.9 | 32.3 | 4.3 | 22.6 | 2.8% | +10% | 17% | 29% |
| HWKN | 2.8 | 34.3 | 2.7 | 17.3 | 3.3% | +9% | 11% | 12% |
| KWR | 2.7 | 27.8 | 1.7 | 13.5 | 2.8% | +8% | 8% | 5% |
| FUL | 2.7 | 13.8 | 1.3 | 7.9 | 3.7% | +1% | 11% | 7% |
| IOSP | 2.4 | 20.1 | 1.2 | 12.8 | 2.0% | +3% | 7% | 10% |
| MTX | 2.0 | — | 1.2 | 39.4 | 6.1% | +4% | -1% | -1% |
| CC | 1.9 | — | 0.9 | 9.5 | 11.3% | -0.9% | 4% | 5% |
| Median of these 10 | 25.0 | 1.4 | 12.9 | 4.4% | +3% | 9% | 7% |
P/E 46.4 vs. a peer median of 25.0; EV/Sales 3.0 vs. 1.4. NGVT's own P/E sits at the 94th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesMTX and CC have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Ingevity Corporation — questions
- What is Ingevity Corporation's market cap?
- $2.4B.
- What is Ingevity Corporation's P/E ratio?
- 46.4 on trailing twelve-month earnings to 2026-06-30.
- What is Ingevity Corporation's price-to-sales ratio?
- 2.1.
Every figure on this page comes from Ingevity Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.